Targeting the vasculature in cardiometabolic disease
Nabil E. Boutagy, … , Abhishek K. Singh, William C. Sessa
Nabil E. Boutagy, … , Abhishek K. Singh, William C. Sessa
Published March 15, 2022
Citation Information: J Clin Invest. 2022;132(6):e148556. https://doi.org/10.1172/JCI148556.
View: Text | PDF
Review Series

Targeting the vasculature in cardiometabolic disease

Abstract

Obesity has reached epidemic proportions and is a major contributor to insulin resistance (IR) and type 2 diabetes (T2D). Importantly, IR and T2D substantially increase the risk of cardiovascular (CV) disease. Although there are successful approaches to maintain glycemic control, there continue to be increased CV morbidity and mortality associated with metabolic disease. Therefore, there is an urgent need to understand the cellular and molecular processes that underlie cardiometabolic changes that occur during obesity so that optimal medical therapies can be designed to attenuate or prevent the sequelae of this disease. The vascular endothelium is in constant contact with the circulating milieu; thus, it is not surprising that obesity-driven elevations in lipids, glucose, and proinflammatory mediators induce endothelial dysfunction, vascular inflammation, and vascular remodeling in all segments of the vasculature. As cardiometabolic disease progresses, so do pathological changes in the entire vascular network, which can feed forward to exacerbate disease progression. Recent cellular and molecular data have implicated the vasculature as an initiating and instigating factor in the development of several cardiometabolic diseases. This Review discusses these findings in the context of atherosclerosis, IR and T2D, and heart failure with preserved ejection fraction. In addition, novel strategies to therapeutically target the vasculature to lessen cardiometabolic disease burden are introduced.

Authors

Nabil E. Boutagy, Abhishek K. Singh, William C. Sessa

×

Figure 1

Schematic overview of systemic lipoprotein metabolism.

Options: View larger image (or click on image) Download as PowerPoint
Schematic overview of systemic lipoprotein metabolism. Triglyceride-rich...
Triglyceride-rich lipoproteins such as VLDL and chylomicron (CM) are produced by the liver and gut, respectively, which distribute FFAs to various metabolic tissue(s) like muscle, heart, and adipose by interacting with the GPIHBP1-bound endothelial LPL enzyme. LPL activity is regulated by secreted ANGPTL3, ANGPTL4, and ANGPTL8. In subsequent peripheral lipolysis, VLDL and CM are converted into intermediate-density lipoprotein (IDL) and chylomicron remnants (CMRs). In the liver, HL liberates FFAs from IDL and converts them into LDL particles. HL activity is inhibited by ANGPTL4. The liver clears a large portion of remnants (LDL and CMRs) via hepatic receptors (LDLR and LRP1). Under hyperlipidemic conditions, some fractions of LDL or CMRs accumulate and oxidize in the subendothelial space of a large artery, which is subsequently taken up by macrophages that develop into foam cells within atherosclerotic plaques. Liver-derived Apo M complexed with sphingosine-1-phosphate (S1P) on HDL may modulate atherosclerotic plaque progression, first by interacting with endothelial S1P receptors (S1PRs) to maintain vascular integrity and suppress inflammation (lower left), and second, by reducing cholesterol overload of macrophages through the promotion of cholesterol efflux (center of figure).